申请人:Laboratoires Glaxo SA
公开号:US05663179A1
公开(公告)日:1997-09-02
Compounds are described of general formula (I) ##STR1## and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which: Z represents either Het, ##STR2## Het represents an optionally substituted bicyclic or tricyclic ring selected from acricine isoquinolin-1-yl, isoquinolin-3-yl, The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an anti-tumour drug.
化合物的一般公式(I)描述如下:##STR1##及其盐和溶剂合物,包括其生理可接受的盐和溶剂合物,其中:Z代表Het或##STR2##,Het代表从acricine isoquinolin-1-yl、isoquinolin-3-yl中选择的可选择性取代的双环或三环环。公式(I)的新化合物可以使多药耐药癌细胞对化疗药物产生敏感,并可制备用于治疗,特别是用于改善或增加抗肿瘤药物的疗效。